特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
474977

ブタクサ花粉症治療薬:パイプライン製品の分析

Ragweed Pollen Allergy - Pipeline Review, H2 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 35 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.70円
ブタクサ花粉症治療薬:パイプライン製品の分析
出版日: 2020年08月31日
発行: Global Markets Direct
ページ情報: 英文 35 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、ブタクサ花粉症の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、休止中・中止されたプロジェクトなどに関する情報を最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

ブタクサ花粉症 - 概要

ブタクサ花粉症 - 治療薬の開発

  • パイプラインの概要
  • 企業別のパイプライン動向
  • 企業で開発中の製品

ブタクサ花粉症 - 治療薬の評価

  • 投与経路別
  • 分子タイプ別

ブタクサ花粉症の治療薬開発に従事している企業

ブタクサ花粉症 - 薬剤プロファイル

ブタクサ花粉症 - 休止中のプロジェクト

ブタクサ花粉症 - 開発が中止された製品

ブタクサ花粉症 - 製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

List of Tables

List of Tables

  • Number of Products under Development for Ragweed Pollen Allergy, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Ragweed Pollen Allergy - Pipeline by ALK-Abello AS, H2 2020
  • Ragweed Pollen Allergy - Pipeline by Allergy Therapeutics Plc, H2 2020
  • Ragweed Pollen Allergy - Pipeline by Anergis SA, H2 2020
  • Ragweed Pollen Allergy - Pipeline by Biomay AG, H2 2020
  • Ragweed Pollen Allergy - Pipeline by Polyrizon Ltd, H2 2020
  • Ragweed Pollen Allergy - Dormant Projects, H2 2020
  • Ragweed Pollen Allergy - Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development for Ragweed Pollen Allergy, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
目次
Product Code: GMDHC12437IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ragweed Pollen Allergy - Pipeline Review, H2 2020, provides an overview of the Ragweed Pollen Allergy (Immunology) pipeline landscape.

Ragweed allergy occurs when ragweed pollen in the air enters the nose and throat of people who are allergic to that pollen, it can cause allergy and asthma symptoms. Symptoms include sneezing, runny or stuffy nose, itchy throat or inside of ears, hives, and swollen eyelids and itchy eyes. Treatment includes decongestant, antihistamine and nasal corticosteroid.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ragweed Pollen Allergy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Ragweed Pollen Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ragweed Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Ragweed Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Preclinical and Unknown stages are 1, 1, 2 and 1 respectively.

Ragweed Pollen Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ragweed Pollen Allergy (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Ragweed Pollen Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ragweed Pollen Allergy (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ragweed Pollen Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ragweed Pollen Allergy (Immunology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ragweed Pollen Allergy (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ragweed Pollen Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Ragweed Pollen Allergy - Overview
  • Ragweed Pollen Allergy - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Ragweed Pollen Allergy - Therapeutics Assessment
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Ragweed Pollen Allergy - Companies Involved in Therapeutics Development
  • ALK-Abello AS
  • Allergy Therapeutics Plc
  • Anergis SA
  • Biomay AG
  • Polyrizon Ltd
  • Ragweed Pollen Allergy - Drug Profiles
  • Allergan for Ragweed Pollen Allergy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BM-34 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PL-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Pollinex Ragweed - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • short ragweed pollen (Ambrosia artemisiifolia) allergen extract ODT - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Ragweed Pollen Allergy - Dormant Projects
  • Ragweed Pollen Allergy - Discontinued Products
  • Ragweed Pollen Allergy - Product Development Milestones
  • Featured News & Press Releases
  • Nov 08, 2019: ALK to present new phase 3 data demonstrating the efficacy and safety of Ragwitek (short ragweed pollen allergen extract tablet for sublingual use 12 Amb a 1-U) Sublingual Allergy Immunotherapy (SLIT)-Tablets in pediatric patients at ACAAI 2019 Annual Scientific Meeting
  • Feb 16, 2017: ALK submits registration application for ragweed SLIT-tablet in Europe
  • Dec 19, 2014: Anergis Granted U.S. Patent for Ragweed Allergy Vaccine AllerR
  • May 15, 2014: Ragwitek, An Allergy Immunotherapy Tablet For The Treatment Of Signs And Symptoms Of Ragweed Allergy, Is Now Available In Canada
  • Apr 17, 2014: FDA Approves Merck's RAGWITEK Sublingual Tablet as Immunotherapy to Treat Short Ragweed Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Adults
  • Jan 24, 2014: ALK announces posting of briefing documents for FDA Advisory Committee meeting on the ragweed sublingual tablet
  • May 08, 2013: Merck Announces FDA Acceptance Of Biologics License Application For Investigational Ragweed Pollen Sublingual Allergy Immunotherapy Tablet
  • Mar 11, 2013: ALK's Partner Merck Submits BLA To FDA For Marketing Authorization For Ragweed AIT
  • Feb 22, 2013: Merck To Present New Data Analyses Of Its Investigational Ragweed Pollen And Grass Pollen Allergy Immunotherapy Tablets At 2013 AAAAI Annual Meeting
  • Feb 21, 2013: Anergis To Present Preclinical Data On Ragweed Allergy Vaccine Candidate AllerR At AAAAI 2013 Annual Meeting
  • Jun 14, 2012: Anergis Reaches Several Preclinical Development Milestones With Ragweed Pollen Vaccine
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.